M. James Barrett, PhD
General Partner, NEA
Dr. Barrett specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Clovis Oncology, GlycoMimetics, Inc., Inhibitex, Inc. (NASDAQ: INHX), Peptimmune, Inc., PhaseBio Pharmaceuticals, Predictive Biosciences, Psyadon Pharmaceuticals, Roka Bioscience, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., and Targacept, Inc. (NASDAQ: TRGT). Dr. Barrett formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca) and Pharmion (acquired by Celgene). Prior to NEA, Mr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline.
Operating Partner, Phase4 Partners
Mr. Richard has worked with the Phase4 team for twelve years. Mr. Richard assists with strategic and commercial diligence activities and has represented Phase4 Partners on the board of Targacept (TRGT), Altus and Immgenics (acquired by Abgenix). He is also Senior Business Advisor at Phase4 Partners' portfolio companies, Albireo and Nabriva.
Mr. Richard is also a partner with Georgia Venture Partners, a seed stage venture company investing in Georgia biosciences, and a board member of Biota pharmaceuticals (BOTA). He was previously at SEQUUS where he was responsible for negotiating the acquisition of the company by ALZA (a subsidiary of Johnson & Johnson) and he was the CEO and co-founder of Impath Inc., which became part of Genzyme.
Kleanthis G. Xanthopoulos, Ph.D.
President & Chief Executive Officer, Regulus Therapeutics Inc.
Kleanthis G. Xanthopoulos, Ph.D. is the President & Chief Executive Officer of Regulus Therapeutics Inc. joining Regulus around its formation in 2007. Prior to that, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a Director until its acquitision by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Sente Inc., Apricus Bioscience, Inc. and a member of the executive board of BIOCOM, and Southern California's life science industry association.
CSO, Zosano Pharma
Dr. Daddona is the founding officer of Zosano, and brings over 30 years of pharmaceutical research and development experience to the company. Prior to spinning off Zosano in 2006, he served as Vice President, Scientific Leader of The Macroflux® Internal Venture, one of Johnson & Johnson’s first Internal Ventures. Previously he was Vice President of Macroflux® Technology Development and Biological Sciences at ALZA Corporation in Mountain View Ca. and held an appointment as Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, he served as Vice President, Immunobiology Research at Centocor, in Malvern Pa., where he focused on preclinical development of therapeutic monoclonal antibodies. Most notably he is a co inventor on the original Remicade patents. Prior to joining Centocor, he served as Associate Professor of Biological Chemistry and Internal Medicine at the University of Michigan. Dr Daddona earned his Ph.D. from the University of Connecticut and post-doctoral training at Duke University.
CEO, Zosano Pharma
Prior to joining Zosano Pharma in 2011, Vikram Lamba was Chief Financial Officer of Predictive Biosciences, Inc. since July 2008. Mr. Lamba served as Vice President of Corporate Development at Advanced Medical Optics, where he was responsible for many significant merger and acquisition deals and strategic alliances, including its acquisition of Intralase Corp. Mr. Lamba served as Vice President for Finance and Chief Financial Officer of Geneohm Sciences, Inc. Mr. Lamba has over 16 years of global experience in various positions with Burmah Castrol PLC and Bayer AG. He served for Castrol in Sales & Marketing and Business Development in India and Singapore for 8 years. During his 8 years with Bayer in Canada, Germany and US, he held positions of significant responsibility in areas of General Management, Mergers & Acquisitions and Finance. He has an undergraduate degree in Mechanical Engineering. Mr. Lamba received his MBA from The Wharton School of the University of Pennsylvania and Asian Institute of Management.
Bruce Steel, CFA
Managing Director, BioMed Ventures
Mr. Steel is an innovative and entrepreneurial leader with extensive investment, operational, and business development experience in the biotechnology sector. In addition to serving as Managing Director of BioMed Ventures, Mr. Steel serves as an officer on the executive team of BioMed Realty (NYSE:BMR). From 2005 until its acquisition in 2008, he was Chief Executive Officer and Co-Founder of Rincon Pharmaceuticals, a genetic engineering biotechnology company. Mr. Steel was previously Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences, both leading San Diego-based biotech companies. He received his Bachelor of Arts degree from Dartmouth College, his Masters of Business Administration degree from the Marshall School of Business at the University of Southern California, and holds the designation of Chartered Financial Analyst.